New Generation Vaccine Induces Effective Melanoma-Specific CD8+ T Cells in the Circulation but Not in the Tumor Site
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Although increasing evidence suggests that CTL are important to fight the development of some cancers, the frequency of detectable tumor-specific T cells is low in cancer patients, and these cells have generally poor functional capacities, compared with virus-specific CD8+ T cells. The generation with a vaccine of potent CTL responses against tumor Ags therefore remains a major challenge. In the present study, ex vivo analyses of Melan-A-specific CD8+ T cells following vaccination with Melan-A peptide and CpG oligodeoxynucleotides revealed the successful induction in the circulation of effective melanoma-specific T cells, i.e., with phenotypic and functional characteristics similar to those of CTL specific for immunodominant viral Ags. Nonetheless, the eventual impact on tumor development in vaccinated melanoma donors remained limited. The comprehensive study of vaccinated patient metastasis shows that vaccine-driven tumor-infiltrating lymphocytes, although activated, still differed in functional capacities compared with blood counterparts. This coincided with a significant increase of FoxP3+ regulatory T cell activity within the tumor. The consistent induction of effective tumor-specific CD8+ T cells in the circulation with a vaccine represents a major achievement; however, clinical benefit may not be achieved unless the tumor environment can be altered to enable CD8+ T cell efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · cited 1×
“In humans, increased numbers of regulatory T cells within tumors have been associated with continuous tumor growth and reduced survival (43).”
BackgroundPhenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544
Sakaguchi, S. (2005) · Nature Immunology · doi:10.1038/ni1178 · Cited by 2,669 · cited 1×
“However, the coexpression of FoxP3 and CD25 on CD4 T cells has been defined as the most appropriate marker of regulatory T cells currently available (40).”
BackgroundUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 1×
“, suppressive dendritic cells, expression of indoleamine 2,3-dioxygenase (39)), the presence of regulatory T cells may have a major influence, because they are known to hamper effective T cell functionality.”
BackgroundRegulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo
Chen, M.-L., Pittet, M. J., Gorelik, L., Flavell, R. A., Weissleder, R., von Boehmer, H., & Khazaie, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408197102 · Cited by 806
Immune Activation and CD8+ T-Cell Differentiation towards Senescence in HIV-1 Infection
Papagno, L., Spina, C. A., Marchant, A., Salio, M., Rufer, N., Little, S., Dong, T., Chesney, G., Waters, A., Easterbrook, P., et al. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020020 · Cited by 478 · cited 1×
“Therefore, the possibility for a cancer vaccine to drive tumor-specific T cells to display phenotype similar to that of cells specific for these two persistent viruses may be an encouraging sign of efficacy and suggests a strong level of stimulation (22, 23).”
BackgroundSelf-citationHuman CD8+ T-cell differentiation in response to viruses
van Lier, R. A. W., ten Berge, I. J. M., & Gamadia, L. E. (2003) · Nature Reviews Immunology · doi:10.1038/nri1254 · Cited by 297 · cited 1×
“At that time, Melan-A-specific cells represented a relatively stable population, characterized by a resting “memory” phenotype (CD38Bcl-2) (data not shown) as observed with virus-specific CD8 T cells (21).”
BackgroundRufer, N., Zippelius, A., Batard, P., Pittet, M. J., Kurth, I., Corthesy, P., Cerottini, J.-C., Leyvraz, S., Roosnek, E., Nabholz, M., et al. (2003) · Blood · doi:10.1182/blood-2003-02-0420 · Cited by 182 · cited 1×
“Five-cell aliquots were sorted directly into wells of different 96-V-bottom plates using a FACSVantage SE (BD Biosciences), followed by cDNA preparation and amplification (17).”
MethodSelf-citationGamadia, L. E., van Leeuwen, E. M. M., Remmerswaal, E. B. M., Yong, S.-L., Surachno, S., Wertheim-van Dillen, P. M. E., ten Berge, I. J. M., & van Lier, R. A. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.6107 · Cited by 122
Cited by
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140559 · Cited by 1,179
“The more and vaccination protocols have been shown to stimulate antigenspecific CD8+ T cells in tumor patients, but these CD8+ T cells remain hyporesponsive at the tumor site (Appay et al., 2006).”
BackgroundMelief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
Baitsch, L., Baumgaertner, P., Devêvre, E., Raghav, S. K., Legat, A., Barba, L., Wieckowski, S., Bouzourene, H., Deplancke, B., Romero, P., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46102 · Cited by 845
Self-citationImmunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists
Vollmer, J., & Krieg, A. M. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.12.008 · Cited by 585
Self-citationHailemichael, Y., Dai, Z., Jaffarzad, N., Ye, Y., Medina, M. A., Huang, X.-F., Dorta-Estremera, S. M., Greeley, N. R., Nitti, G., Peng, W., et al. (2013) · Nature Medicine · doi:10.1038/nm.3105 · Cited by 457
TLR-Activated B Cells Suppress T Cell-Mediated Autoimmunity
Lampropoulou, V., Hoehlig, K., Roch, T., Neves, P., Gómez, E. C., Sweenie, C. H., Hao, Y., Freitas, A. A., Steinhoff, U., Anderton, S. M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4763 · Cited by 436
Development of TLR9 agonists for cancer therapy
Krieg, A. M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31414 · Cited by 429
Self-citationCancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
Gajewski, T. F., Woo, S.-R., Zha, Y., Spaapen, R., Zheng, Y., Corrales, L., & Spranger, S. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.02.009 · Cited by 422
CD8+ T cell efficacy in vaccination and disease
Appay, V., Douek, D. C., & Price, D. A. (2008) · Nature Medicine · doi:10.1038/nm.f.1774 · Cited by 393
Self-citationToll-like receptor 9 (TLR9) agonists in the treatment of cancer
Krieg, A. M. (2008) · Oncogene · doi:10.1038/sj.onc.1210911 · Cited by 388
Self-citationPlasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
Hölzel, M., Bovier, A., & Tüting, T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3498 · Cited by 269
The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system
Engel, A. L., Holt, G. E., & Lu, H. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.5 · Cited by 205
Kortylewski, M., Kujawski, M., Herrmann, A., Yang, C., Wang, L., Liu, Y., Salcedo, R., & Yu, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3031 · Cited by 122
“Whereas TLR9 agonist–based therapies have no major toxicity and show some promise, the efficacy of the TLR9-mediated antitumor immune response is limited, which is largely attributed to the immunosuppression observed in cancer patients (1, 5).”
Chapon, M., Randriamampita, C., Maubec, E., Badoual, C., Fouquet, S., Wang, S.-F., Marinho, E., Farhi, D., Garcette, M., Jacobelli, S., et al. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.30 · Cited by 86
“, 2008) but T cell-infiltrating tumor lesions of treated patients are poorly reactive compared with peripheral blood T cells (Appay et al., 2006).”
BackgroundProphylactic and therapeutic implications of toll-like receptor ligands
Hedayat, M., Takeda, K., & Rezaei, N. (2012) · Medicinal Research Reviews · doi:10.1002/med.20214 · Cited by 76
Metadata
- Authors
- Appay, V., Jandus, C., Voelter, V., Reynard, S., Coupland, S. E., Rimoldi, D., Lienard, D., Guillaume, P., Krieg, A. M., Cerottini, J.-C., Romero, P., Leyvraz, S., Rufer, N., & Speiser, D. E.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-08-01
- Volume
- 177
- Issue
- 3
- Pages
- 1670-1678
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2144350507
- Cited by
- 149
- References
- 9
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.